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Severe acute respiratory syndrome (SARS) is a systemic disease characterized by both lung pathology and
widespread extrapulmonary virus dissemination causing multiple organ injuries. In this regard, renal dysfunction
is an ominous sign in patients with SARS. Indeed, clusters of SARS coronavirus (SARS-CoV) particles have been
detected in the cytoplasm of renal tubular epithelial cells in postmortem studies, explaining the presence of
infectious virus in the urine of SARS patients. In order to investigate the potential SARS-CoV kidney tropism, we
have evaluated the susceptibility of human renal cells of tubular and glomerular origin to in vitro SARS-CoV
infection. Immortalized cultures of differentiated proximal tubular epithelial cells (PTEC), glomerular mesangial
cells (MC), and glomerular epithelial cells (podocytes) were found to express the SARS-CoV receptor angiotensin-
converting enzyme 2 on their surface. Productive infection, however, occurred only in PTEC but not in glomerular
cells. A transient infection with poor virus production was observed in MC, whereas podocytes were not permissive
to SARS-CoV infection. In contrast to the cytopathic infection of the Vero E6 cell line, SARS-CoV did not cause overt
cytopathic effects in PTEC or MC. Of interest, PTEC, but not MC, maintained stable levels of SARS-CoV produc-
tion in serial subcultures, suggesting a persistent state of infection. In this regard, a SARS-CoV variant with
increased replication capacity in PTEC was selected after four serial subculture passages. This SARS-CoV variant
acquired a single nonconservative amino acid change from glutamic acid (E) to alanine (A) at position 11 in the viral
membrane (M) protein. The E11A point mutation was sufficient for enhanced SARS-CoV replication and persis-
tence in PTEC when introduced in a SARS-CoV recombinant infectious clone. These findings indicate that human
PTEC may represent a site of SARS-CoV productive and persistent replication favoring the emergence of viral
variants with increased replication capacity, at least in these kidney cells.
The severe acute respiratory syndrome (SARS) emerged in
China and spread to several countries worldwide in a few
months, resulting in the infection of 8,096 people and 774
deaths from 2002 to 2003 (52). A novel human coronavirus
(SARS-CoV) was independently isolated from SARS patients
on three different continents (12, 27, 28, 38). Human-to-human
SARS-CoV transmission was contained in the same year; how-
ever, animal-to-human transmission has been documented, im-
plying that the virus could reemerge as a human pathogen.
Indeed, the full eradication of SARS-CoV might be extremely
difficult since its natural host seems to be a wild rather than a
domestic animal (19, 32).
The main target organs of SARS-CoV are the lungs, which
can be severely damaged by the infection, causing acute respi-
ratory distress syndrome, which is frequently fatal (39). Several
reports, however, have highlighted that SARS patients often
showed evidence of lymphoid tissue, liver, and kidney dysfunc-
tions (13, 16, 49). In particular, a small proportion (6.7%) of
SARS patients suffered acute renal impairment; interestingly,
the involvement of the kidney in SARS cases has been associ-
ated with a high (91.7%) mortality rate (5). Immunohisto-
chemistry, in situ hybridization, and electron microscopy ex-
amination of autopsy samples obtained from these patients
revealed SARS-CoV virions, RNA, and/or antigen in lung and
in a number of other organs, including the kidneys (16). These
observations indicate that SARS-CoV causes a systemic infec-
tion with widespread extrapulmonary dissemination with viral
shedding not only in respiratory secretions, but also in stool
and urine (23, 54).
This broad dissemination of SARS-CoV infection has been
correlated, in part, to the multiple-organ expression of angio-
tensin-converting enzyme 2 (ACE2), which serves as the cell
surface SARS-CoV receptor (21, 31), and to a lesser extent
coreceptors such as liver-specific ICAM-grabbing non-integrin
(L-SIGN) (24). ACE2 is expressed by type 1 and 2 pneumo-
cytes, enterocytes of the small intestine, and at the brush bor-
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der of the proximal tubular epithelial cells (PTEC) of the
kidney (17). In this regard, it is interesting to note that the
Vero cell line, which was crucial in the successful isolation of
SARS-CoV from nasopharyngeal material of infected patients,
was derived from the kidney of an African green monkey (12,
14, 44, 51). In addition, cell lines of human kidney origin have
shown susceptibility to SARS-CoV infection and, among these,
the human embryonic kidney 293 cells support SARS-CoV
productive infection (56).
The goal of our study was to investigate the susceptibility of
the main cell types present in the nephron in order to charac-
terize a potential tropism of SARS-CoV infection in the kid-
ney. In this regard, glomerular mesangial cells (MC) are spe-
cialized pericytes of vascular smooth muscle origin exerting
several physiological functions, such as the control of glomer-
ular hemodynamics, clearance of macromolecules, and im-
mune complexes, whereas epithelial cells (podocytes) play an
essential role in glomerular perm-selectivity (1, 25). Finally,
PTEC are responsible for the readsorption of about 60% of the
glomerular ultrafiltrate (34).
In the present study, immortalized human PTEC, MC, and
podocytes derived from glomerular and cortical tubules were
selected as in vitro models to test their susceptibility to SARS-
CoV infection. Unexpectedly, SARS-CoV productive and per-
sistent infection was only supported by PTEC and was associ-
ated with the emergence of a single-amino-acid mutation in the
membrane (M) protein.
MATERIALS AND METHODS
Cells. The Vero E6 cell line was obtained from the Istituto Zooprofilattico of
Brescia, Italy, and was maintained in Eagle’s minimum essential medium
(EMEM; Cambrex Bio Science, Verviers, Belgium) supplemented with 10%
fetal bovine serum (FBS) and penicillin-streptomycin (complete medium). The
immortalized human PTEC line was previously characterized (42). Differenti-
ated glomerular cell lines were obtained by immortalization through the infec-
tion with an adenovirus 5-simian virus 40 hybrid of pure primary cultures estab-
lished as described previously (6). Individual foci of immortalized cells were
subcultured and characterized on the basis of cell morphology, functional tests,
and the expression of cell-specific antigens, according to established criteria (48).
MC and podocyte lines were selected and used between passages 25 and 45, as
reported previously (7–9). PTEC were maintained in RPMI 1640 (Cambrex Bio
Science) supplemented with 10% FBS, whereas MC were maintained in RPMI
1640 plus 20% FBS. Podocytes were cultivated in Dulbecco’s MEM (DMEM,
Cambrex Bio Science) supplemented with 20% FBS.
Virus. The SARS-CoV HSR1 strain was isolated from a sputum sample of an
Italian male who traveled in 2003 in Asia and returned to Italy affected by SARS.
The sputum was collected at the peak of illness and stored at 80°C for 3 weeks
prior to virus isolation on Vero cells. Primary, secondary, and tertiary viral stocks
were generated in Vero cells as previously described (51). In order to measure
the virus titer present in the viral stocks, a plaque assay was optimized in Vero
E6 cells (40). Briefly, confluent Vero E6 cells (1.5  106 cells) seeded in six-well
plates (Falcon, Becton Dickinson Labware, Lincoln Park, NJ) were incubated in
duplicate with 1 ml of phosphate-buffered saline (PBS) containing 100 l of
SARS-CoV in 10-fold serial dilutions. After 1 h of incubation, the viral inoculum
was removed and 1 ml of carboxymethylcellulose (Sigma Chemical Corp., St.
Louis, MO) with DMEM supplemented with 1% FBS was overlaid on each well.
After 6 days of incubation, the cells were stained with 1% crystal violet (Sigma)
in 70% methanol. The plaques were counted after examination with a stereo-
scopic microscope (SMZ-1500; Nikon Instruments, Firenze, Italy) and the virus
titer was calculated in PFU/ml. The entire SARS-CoV HSR1 genome sequence
is deposited in the GenBank database under accession no. AY323977.
Infections. Vero E6 cells, PTEC, MC, and podocytes (4  106 cells/flask in 10
ml) were seeded in 25-cm2 tissue culture flasks (Falcon) and incubated for 24 h.
Cells at 70 to 80% confluence were washed twice with PBS and inoculated with
500 l of virus suspension (tertiary stock HSR1-III) corresponding to 4  105
PFU per flask and to a multiplicity of infection (MOI) of 0.1. Inoculated cell
cultures were incubated at 37°C for 1 h before being washed five times with
EMEM and incubated for 96 h in complete medium. A mock infection was
performed in parallel for each cell line. The cell monolayers were examined daily
for cytopathic effects (CPE). Aliquots of culture supernatants were also collected
daily and stored at 80°C; the cells were trypsinized and spun to obtain a cell
pellet. The remaining cultures were trypsinized 3 days postinfection (p.i.) and
diluted 1:2 in fresh complete medium. This procedure was serially repeated every
3 days up to four consecutive times. During each passage, supernatants and cell
pellets were harvested every 24 h and stored at 80°C. The virus titer present in
the supernatant of each passage was determined by open reading frame 1b
(ORF-1b) real-time PCR and by a plaque infectivity assay in Vero E6 cells as
described previously (51). To determine the ability of SARS-CoV present in the
first and last supernatants to reinfect either PTEC or Vero E6 cells, 1.5  106
cells were seeded in six-well plates (Falcon) and, 24 h later, they were inoculated
with MOIs of 0.03 and 0.006, respectively. Cell cultures were incubated at 37°C
for 1 h and then washed five times with EMEM and incubated for 96 h in
complete medium. The kinetics of viral replication were determined by quanti-
fication of ORF-1b in aliquots of the supernatants collected daily up to 7 days.
ACE2 cell surface expression. Renal epithelial cells (2  105) were detached
with Accutase (Uptima Interchim, Montluc¸on, France) and washed with PBS
containing 2% FBS. One microgram of a polyclonal antibody (Ab) against
human ACE2 (R&D Systems, Minneapolis, MN) was applied to 2 105 cells for
30 min at 4°C. After 2 washes with PBS containing 2% FBS, cells were exposed
to 1 g of swine anti-goat phycoerythrin-conjugated Ab (G50001; Caltag Labo-
ratories, Burlingame, CA) for 30 min at 4°C. The cells were washed twice with
PBS containing 2% FBS and 0.1% Na-azide, fixed in 2% formaldehyde–PBS, and
subjected to flow cytometry using a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ), and the results were analyzed by the CellQuest program
(Becton Dickinson).
Real-time RT-PCR mRNA analysis. Total RNA was isolated by the TRIzol
method (Invitrogen, Carlsbad, CA). cDNA was synthesized from 2 g of total
RNA using Superscript II reverse transcriptase (RT) (Invitrogen) with random
primers. A real-time PCR that amplifies a 141-bp fragment specific for the
transcript of the nucleocapsid protein was used to detect and quantify SARS-
CoV in the infected cells. The assay used ABI-7700 Prism instrumentation
(Applied Biosystems, Foster City, CA), with primers and probe designed with the
associated Primer Express software. The following primer pair and probe were
added to the universal PCR master mix (Applied Biosystems) at 200 and 100 nM,
respectively, in a final volume of 25 l: forward primer, 5-AACCAACCTCGA
TCTCTTGTAGATCT-3; reverse primer, 5-TCCATTCTGGTTATTGTCAG
TTGAA-3; and probe, 6-carboxyfluorescein–TCTCTAAACGAACAAATTA
AAATG TCTGATAATGGAC–6-carboxytetramethylrhodamine. The cycling
conditions were as follows: 2 min at 50°C, 10 min at 95°C, and then 40 cycles of
15 s at 95°C and 1 min at 60°C. The standard was obtained by cloning the 141-bp
fragment into the pCR2.1 plasmid using the TA cloning kit (Invitrogen). A linear
distribution (r  0.99) was obtained between 101 to 108 copies. To correct for
intersample variations in RT-PCR efficiency and errors in sample quantification,
a set of 18S PCRs was performed as an invariant endogenous control in the assay.
Primer pair and probe for 18S were obtained from Applied Biosystems and used
according to the manufacturer’s directions.
Viral RNA was purified from 140 l of the cell supernatant using the viral
RNA Mini kit (Qiagen). Full-length genomic RNA was retrotranscribed by using
Superscript II RT (Invitrogen) with random primers. Briefly, the real-time PCR
of a 77-bp fragment of ORF-1b was obtained by using the following primer pair
and probe, added to the universal PCR master mix (Applied Biosystems) at 200
nM in a final volume of 25 l: primer BNITMSARS1, 5-TTATCACCCGCGA
AGAAGCT-3; primer BNITMSARAS2, 5-CTCTAGTTGCATGACAGCCCT
C3; and probe BNITMSARS, 6-carboxyfluorescein-TCGTGCGTGGATTGGC
TTTGATGT-6-carboxytetramethylrhodamine (40). The standard was obtained
by cloning the 77-bp fragment into the pCR2.1 plasmid using the TA cloning kit
(Invitrogen). A linear distribution (r  0.99) was obtained between 101 and 108
copies.
Sequencing of the SARS-CoV HSR1 genome released by infected PTEC. After
reverse transcription, amplification of virus genome sequences was carried out
with 68 partially overlapping primers encompassing the whole viral genome by
using Pfu TURBO DNA polymerase (Stratagene, La Jolla, CA). Each 750-bp
fragment was gel isolated by means of a QIAQuick gel extraction kit (Qiagen)
and directly sequenced from both directions inward and outward. SeqScape
version 2.0 (Applied Biosystems) software was used for base identification, ed-
iting, and assembly of the fragments. The cDNA of the M coding sequence was
amplified by the primer pair MF (CCTGATCTTCTGGTCTAAACG) and MR
(CTCTGCTATTGTAACCTGGAAGTC) with the Pfu TURBO DNA polymer-
ase (Stratagene). The PCR products were gel purified by means of a QIAQuick
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gel extraction kit (Qiagen) and cloned into pZERO vector (Invitrogen). Indi-
vidual colonies were inoculated, and after plasmid extraction, sequences of
individual clones were obtained with M13 and M13 primers by an automatic
sequencer (ABI Prism 3100; Applied Biosystems).
Insertion of mutations in an infectious clone of SARS-CoV. Two nucleotide
changes, G26425A and A26429C, causing EK and EA amino acid mutations,
respectively, were inserted by site-directed mutagenesis into cDNA clones and
used to construct and rescue an infectious clone obtained from the recombinant
Urbani SARS-CoV strain (GenBank accession no. AY278741), as described
previously (57). In brief, the mutated F fragment and wild-type (WT) fragments
A through E were amplified in Escherichia coli, isolated by restriction digestion,
and separated on agarose gels. The fragments were then gel extracted and ligated
together to generate a genome-length cDNA. Full-length genomic transcripts
were generated using mMessage mMachine kits from Ambion, which were trans-
fected directly into Vero E6 cells. Cells were seeded and monitored for evidence
of CPE, while the supernatants were harvested and passaged as described above.






The infectious and all recombinant viruses produced in this study were
isolated, sequenced, confirmed, and propagated on Vero E6 cells in DMEM
containing 10% fetal clone II, 10% tryptose phosphate broth, and 1 gentami-
cin-kanamycin.
RESULTS
Susceptibility of human kidney cell lines to SARS-CoV in-
fection. It is well established that the susceptibility of cell lines
derived from different organs and tissues to SARS-CoV infec-
tion is strongly influenced by their level of expression of the
virus receptor ACE2 (31, 33, 41). Thus, in order to determine
the capacity of SARS-CoV to infect human cells from different
components of the renal corpuscle, ACE2 surface expression
was determined by anti-ACE2 polyclonal Ab staining and
FACS analysis of PTEC, MC, and podocytes in comparison to
Vero E6 cells. The expression of ACE2 was highest in Vero E6
cells in comparison to all human kidney-derived cell lines;
small differences of expression were noted among the latter
with the gradient PTEC  MC  podocytes (Fig. 1).
A key feature of CoVs is their unique transcription strategy
that leads to the synthesis of a nested set of 3-coterminal
subgenomic mRNAs, encoding structural and accessory pro-
teins (45). The synthesis of each subgenomic mRNA involves a
discontinuous step by which the body transcription regulatory
sequence is fused to the genomic 5 leader sequence. The
fusion of 5 leader and 3 body transcription regulatory se-
quences during discontinuous transcription corresponds to the
individual transcription units (45, 47). By sequencing the junc-
tion between the leader sequence and the nucleocapsid gene of
SARS-CoV HSR1 obtained from Vero E6-infected cells, a
primer pair and probe specific for the detection of the sub-
genomic nucleocapsid RNA were designed. The replication
kinetics of SARS-CoV in Vero E6 and kidney cell lines are
shown in Fig. 2, as measured by real-time PCR assay for nu-
cleocapsid transcripts in infected cells and for ORF-1b viral
genomes in the supernatant. The peak of viral replication was
reached 48 h p.i. in Vero E6 cells (Fig. 2). Similar to Vero E6
cells, a titer increase of 5 log10/ml above the input virus was
achieved in PTEC 96 h p.i.; the levels of intracellular nucleo-
capsid transcripts were, however, approximately 1,000-fold
lower in PTEC than in Vero E6 cells. Although the levels of
SARS-CoV HSR1 nucleocapsid transcripts in MC were 2 log10
above the input virus detectable 24 h p.i., they were signifi-
cantly lower than those observed in PTEC. In contrast, the
FIG. 1. ACE2 expression in kidney cell lines. Kidney cell lines
derived from African green monkeys (Vero E6), human kidney PTEC,
MC, and podocytes were analyzed for ACE2 expression by labeling the
cell surface with an anti-ACE2 polyclonal Ab. The full histograms
indicate cells testing positive for ACE2 expression, whereas the open
histograms represent the staining with a control Ab (swine anti-goat
phycoerythrin-conjugated secondary Ab). The number on the upper
right indicates the percentage of ACE2 cells.
FIG. 2. Kinetics of SARS-CoV replication in kidney cells. Vero E6
cells, PTEC, MC, and podocytes were infected with SARS-CoV HSR1 at
an MOI of 0.1. Virus replication was measured by real-time PCR of the
full genome (Œ) in the supernatant of infected cells harvested every 24 h
up to 4 days p.i. The quantification of subgenomic transcripts was carried
out by real-time PCR on retrotranscribed cDNA obtained from infected
cells every 24 h up to 4 days p.i. The nucleocapsid (N) log10 copy number
(f) was normalized by 50 ng of 18S RNA measured by real-time PCR.
Values represent the mean number of ORF-1b copies  standard devi-
ation expressed as log10/ml obtained in three independent experiments.
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nucleocapsid transcripts did not increase in virus-exposed
podocytes over the background levels (Fig. 2).
In order to correlate the copy number of ORF-1b obtained
by real-time PCR with the number of infectious virions, a
plaque assay was performed in Vero E6 cells with the super-
natants obtained from infected human kidney cells and Vero
E6 cells as a control. The kinetics of infectious virus production
showed that titers of 1.07  105 and 1.34  106 PFU/ml were
obtained 96 h p.i. in PTEC and Vero E6 cells, respectively,
whereas the maximum yield of infectious virus in MC culture
supernatants was 3.6  102 PFU/ml 72 h postinfection (Fig. 3).
These results support a direct correlation between the number
of the viral genomes and the infectious virus titers released by
infected cells (Fig. 2 and 3, respectively) confirming previous
observations that approximately 2 to 3 log10 of SARS-CoV
genomes are required to form a single plaque in Vero E6 cells
(40, 51).
A cytopathic effect (CPE) appeared as early as 48 h after
virus inoculation in Vero E6 quickly spreading to the entire
cell monolayer by 72 h (Fig. 4). In contrast, PTEC and MC
viability was only slightly affected by virus replication, as dem-
onstrated by Trypan blue dye exclusion and lack of evidence of
a SARS-CoV-induced CPE (Fig. 4). The percentage of viable
PTEC and MC ranged constantly between 80 and 90%, in spite
of the different levels of virus replication (that were higher in
PTEC than in MC; Fig. 2 and 3). We cannot exclude that the
lack of evidence of a CPE in PTEC might in part be dependent
on both slower kinetics and lower efficiency of viral replication
in PTEC compared to Vero E6 cells.
SARS-CoV causes a persistent infection of PTEC but not
MC. Since the infection of PTEC and MC cultures with SARS-
CoV did not result in a clear CPE, we investigated the possi-
bility that SARS-CoV might establish a persistent infection in
these cells, as previously observed in the colonic epithelial
LoVo cell line, in which SARS-CoV replicates with no evi-
dence of CPE (2) and in Vero E6 cells after the acute lytic
phase of replication (36, 55). For this purpose, infected PTEC
and MC cultures were regularly split every 3 days up to four
passages. The supernatants were collected prior to each cell
subcultivation and tested for the presence of ORF-1b by real-
time PCR: time zero hours (T0) defined the supernatant har-
vested prior to the first subcultivation, and the following col-
lections were indicated by serial numbers up to four cell
subcultivations in five independent experiments. Continuous
production of SARS-CoV was maintained in PTEC within the
range of 7.44 to 8.27 log10 copies/ml in the absence of evident
CPE in three out of five independent experiments (Fig. 5). In
contrast, the viral copy number in the supernatants of MC
decreased from 5 to approximately 2 log10 copies/ml after four
serial cell divisions. The infectious virus titers in T0 and T4
PTEC supernatants were 3.3  104 and 4.2  104 PFU/ml,
respectively, as tested in Vero E6 cells.
Evolution of SARS-CoV in persistently infected PTEC. In
order to evaluate whether viral mutations evolved during the
persistent infection of human PTEC, sequencing of the entire
SARS-CoV genome was carried out on genomic RNA ex-
tracted from T4 supernatant. The alignment of SARS-CoV
sequences obtained from the T4 supernatant with the reference
HSR1 strain (GenBank accession no. AY323977) revealed the
substitution of only 1 nucleotide out of 29,751 mapping in the
coding sequence of the M protein at position 26429 and re-
sulting in a mutation of glutamic acid (E) into alanine (A) at
position 11.
In order to better characterize the kinetics of the emergence
of viruses carrying this mutation, the M coding sequence was
amplified from SARS-CoV present in the supernatant col-
lected prior to each cell subcultivation. By cloning and se-
quencing an average of 10 independent clones from T0 to T4,
FIG. 3. Kinetics of SARS-CoV growth. The supernatants from in-
fected PTEC (f), MC (F), and Vero E6 (Œ) cells, harvested every 24 h
up to 4 days p.i., were tested in a Vero E6 plaque assay to determine
the levels of infectious virus. Values represent the mean PFU  stan-
dard deviation, expressed as log10/ml obtained in three independent
experiments.
FIG. 4. Cell viability after SARS-CoV HSR1 infection of Vero E6
and human kidney cells. Cells were exposed to 4  105 PFU of SARS-
CoV HSR1 and stained with Trypan blue dye after 72 h p.i. Photographs
were taken using a digital camera connected to the light microscope at a
magnification of 40. CPE (dark) was evident in Vero E6 cells, whereas
SARS-CoV-infected human kidney epithelial cells did not show de-
creased viability in comparison to uninfected control cell cultures.
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we observed that the E11A mutation firstly appeared in the T3
supernatant in 2 out of 10 clones and became dominant (in 10
out 10 clones) in T4 (Fig. 6). The viral stock HSR1-III was
characterized by a mixture in which one variant had a G3A
change at position 26425 leading to amino acid change E10K.
This variant was selected during the serial subcultivation and
disappeared with the emerging E11A mutation. These results
suggest that the E11A mutation is selected as consequence of
virus adaptation to replicate in PTEC cells.
Analysis of SARS-CoV M mutant replication in PTEC. In
order to test whether the emergence of E11A mutation was
consequent to SARS-CoV adaptation in PTEC, the initial (T0)
and the last (T4) supernatants from one of the three experi-
ments reported in Fig. 5 were further analyzed. The virus titer
was determined in these supernatants by either plaque assay on
Vero E6 cells or ORF-1b real-time PCR (40, 51). T0 and T4
supernatants contained 3.3  104 and 4.2  104 PFU/ml and
3.7  107 and 7.6  107 ORF-1b copies/ml, respectively. In
order to evaluate differences in replication efficiency in T0 and
T4 supernatants, cultures of PTEC were infected at the MOI of
0.03, lower than the MOI of 0.1 used in the experiments shown
in Fig. 2. In addition, PTEC were incubated with a 1:1 mixture
of T0 and T4 supernatants containing 5  10
4 PFU/each in
order to reveal a potential interference between virus variants
generated during PTEC persistent infection. Cultures incu-
bated with the HSR1-III virus were maintained in parallel as a
control. The kinetics of SARS-CoV replication, as measured
by ORF-1b real-time PCR of T0, T4, and the T0  T4 mixture,
are shown in Fig. 7. The T4 virus showed a replication capacity
higher than the T0 virus in terms of both kinetics and levels of
ORF-1b expression, whereas PTEC infected with a T0  T4
mixture showed intermediate kinetics, but, ultimately, the lev-
els of virus replication were comparable to those of the T4 virus
(Fig. 7, left panel). In contrast, the levels of ORF-1b copies
present in the supernatant of Vero E6 cells infected with either
T0 or T4 viruses were superimposable (Fig. 7, right panel). This
finding suggests that a superior replicative capacity in PTEC is
conferred by the E11A mutation in the M glycoprotein.
Replication kinetics of SARS-CoV infectious clone contain-
ing mutations in the M protein. The contribution of the M
protein E10K and E11A mutations to virus replication in
PTEC and Vero E6 cells was further investigated in the context
of the recombinant viruses derived from an infectious clone
obtained from SARS-CoV Urbani (57). The kinetics of viral
replication of WT and isogenic recombinant viruses encoding
the E11A or E10K mutations are shown in Fig. 8. The E11A
mutant virus replicated more efficiently than WT virus in
PTEC, whereas E10K mutant virus showed replication kinetics
similar to those of WT virus (Fig. 8A). The replication kinetics
of the three viruses were indistinguishable in Vero E6 cells
when cells were infected with WT and mutant viruses at the
MOI of 0.00006; nonetheless, the levels of ORF-1b transcripts
24 h p.i. were approximately 1 log10 superior in Vero E6 cells
infected with the E11A mutant to those from cells infected
with WT virus (Fig. 8B). The replicative advantage of the
E11A mutation for replication in PTEC was further confirmed
by plaque assay in Vero E6 cells in supernatants harvested at
FIG. 5. Persistent virus production in PTEC but not in MC. Cells
were infected with SARS-CoV HSR1 at an MOI of 0.1. After 3 days,
cultures were split and this procedure was repeated every 3 days up to
four passages. Cultivation passages are indicated with a T, and the
number in subscript indicates the serial passage. At each passage, 50%
of the cells were seeded in fresh medium. The SARS-CoV copy num-
ber was calculated by real-time PCR of ORF-1b in cell supernatants
collected prior to cell subculture. Values represent the mean number
of ORF-1b copies standard deviation expressed as log10/ml obtained
in three independent experiments.
FIG. 6. Proportion of viral quasispecies in the M protein following
serial subculturing of PTEC. The percentage is relative to 10 clones
obtained from SARS-CoV HSR1-III passaged three times in Vero E6
cells and each time point from T0 to T4.
FIG. 7. Kinetics of SARS-CoV HSR1 replication in PTEC and
Vero E6 cells infected with the supernatant obtained from the T0
culture prior to cell division and the T4 subculture. PTEC and Vero E6
cells were infected at MOIs of 0.03 and 0.006, respectively. Both PTEC
and Vero E6 cells were also incubated with a 1:1 mixture of T0 and T4
supernatants containing 5  104 PFU/each. Replication kinetics were
measured by real-time PCR of ORF-1b in the supernatant harvested
every 24 to 48 h p.i. Values represent the mean number of ORF-1b
copies  standard deviation expressed as log10/ml obtained in three
independent experiments.
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168 h p.i. (Fig. 8C). These results confirmed that the E11A
mutation is advantageous for SARS-CoV replication.
DISCUSSION
In this study, we have shown that differentiated human renal
tubular epithelial cells (PTEC) and, to a lesser extent, glomer-
ular MC supported productive in vitro infection of SARS-CoV.
In contrast, glomerular epithelial cells (podocytes) did not
support productive SARS-CoV replication in spite of expres-
sion of ACE2 on their surface. Unlike Vero E6 cells, PTEC
and MC showed no evidence of CPE or reduced cell prolifer-
ation upon infection by SARS-CoV. Interestingly, SARS-CoV
replicated in MC only transiently, whereas a persistent state of
infection characterized by a stable release of infectious virus
was observed in PTEC. This productive infection profile in
PTEC was associated with the emergence of a viral variant
characterized by a single-amino-acid substitution (E11A) in
the M protein showing a replicative advantage versus WT in
PTEC. This observation was confirmed by the replication ki-
netics of virus derived from an infectious molecular clone in
which the E11A was introduced.
The renal cell lines used in this study maintain phenotypic
and functional features identical to those of the tubular and
glomerular cells in tissue, and for these reasons, they have been
used as models to investigate the interaction between different
viruses and human renal cells (6, 7, 9). For example, human
immunodeficiency virus type 1 was shown to induce distinct
pathogenic effects in glomerular and tubular cells, mimicking
the pathological features of HIV-associated nephropathy in
vivo (7, 8). Our in vitro findings support the evidence of kidney
involvement in the natural history of SARS-CoV infection,
providing an experimental model for the virus tropism to the
kidney having potentially relevant implications for SARS
pathogenesis (5, 11, 13, 16). In this regard, extrapulmonary
dissemination of the virus into all major organs, including the
distal renal tubules, has been confirmed in several patients by
electron microscopy, in situ hybridization, and real-time PCR
(16, 29). Our results demonstrate that the tubular epithelial
cells are indeed susceptible to SARS-CoV infection and rep-
lication in vitro. The establishment of productive viral replica-
tion in these cells with release of infectious progeny is in
agreement with the presence of virus in the urine, as detected
in SARS patients (20, 37). Since viruses are much larger than
filterable micromolecules, patient’s viruria is likely a conse-
quence of viral shedding from kidney cells rather than of a
defect in glomerular filtration. In this regard, a significant and
persistent amount of SARS-CoV was detected in the urine of
experimentally infected cynomolgus macaques (30). It should
be noted that acute renal failure has been reported in SARS
cases and that renal tubular epithelial cells represent the main
target of the damage. Actually, about 7% of the SARS patients
developed acute tubular necrosis with no evidence of glomer-
ular pathology (5). Therefore, our study suggests that virus
replication in PTEC might be responsible for, or at least in-
volved in, renal dysfunctions in vivo. Since SARS-CoV infec-
tion of tubular epithelial cells did not cause an overt CPE, the
possibility of either direct or immune-mediated mechanisms of
virus-induced tubular injury should be further investigated.
However, it must be taken into account that even minor func-
tional damage of tubular cells has been linked to a negative
prognosis in individuals infected with SARS CoV (53).
ACE2 has been identified as the receptor for SARS-CoV in
Vero E6 cells (31). ACE2 is abundantly present in humans in
the epithelia of lung and small intestine, heart, testis, and also
kidney (33). In our study, the distinct susceptibility of the
different human renal cells to SARS-CoV infection was in part
correlated to differential levels of ACE2 expression. Indeed,
despite detectable levels of ACE2 expression on both MC and
podocytes, only MC were transiently susceptible, whereas
podocytes were clearly nonpermissive to productive SARS-
CoV infection. This observation suggests that cofactors or co-
receptors other than ACE2 are required in order to confer full
susceptibility to productive SARS-CoV infection. In this re-
gard, SARS-CoV has been shown to interact with receptors
distinct from ACE2 to gain entry into cells (3). In particular,
DC-SIGN (dendritic cell-specific ICAM-grabbing non-inte-
grin) and L-SIGN, both members of the C-type lectin family of
receptors, have been shown to serve as SARS-CoV receptors
independently of ACE2 (18, 24). We cannot exclude that dif-
ferential expression of L- or DC-SIGN might influence viral
entry in these cells. In addition, factors other than differential
expression of ACE2 and L- or DC-SIGN likely play a crucial
role in cell susceptibility to SARS-CoV infection, productive
virus replication, and cytopathicity. In this regard, Vero E6
cells are known to lack a functional beta interferon (IFN-	)
FIG. 8. Kinetics of viral replication of WT and mutant infectious
clone (ic) in PTEC (A) and Vero E6 cells (B). Replication kinetics
were measured by real-time PCR of ORF-1b in the supernatant har-
vested every 24 to 48 h p.i. Values represent the mean number of
ORF-1b copies  standard deviation expressed as log10/ml obtained in
two independent experiments. Infectious virus present in the PTEC
supernatant 168 h p.i. (C) was determined in a Vero E6 plaque assay.
Values represent the mean PFU  standard deviation as log10/ml.
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gene, although the African green monkey-derived MA104 cells
are endowed with an intact IFN-	 gene and allow replication
of SARS-CoV as efficiently as Vero cells (46). In this regard,
SARS-CoV has acquired the capacity to curtail the IFN re-
sponses (15, 26). Other cellular factors, however, may be in-
volved in protecting PTEC from SARS-CoV CPE, as observed
in other in vitro models of viral persistence (10).
In addition to cellular factors, however, mutations in the viral
genome occurred during PTEC persistent and productive infec-
tion. Culture supernatants generated during each cell division
were characterized with regard to potential changes in the virus
replication capacity. In this regard, mixed viral populations with
different genotypes can coexist in an equilibrium governed by a
balance between mutations and general selection. In our case,
four serial passages in PTEC were sufficient to select for the fittest
variant. By sequencing the entire viral genome, we demonstrated
that the nonconservative E11A mutation in the M protein was
selected during persistent infection of PTEC and was advanta-
geous for SARS-CoV replication in these cells.
By comparing the sequences available from the Chinese
SARS Molecular Epidemiology Consortium, no changes were
observed in the M glycoprotein at position 11 (4). However, a
variation from glycine (G) to serine (S) was present at position
5 when palm civet sequences were compared to the human
sequences collected during the epidemic. Although the role of
G5S in viral adaptation and pathogenesis is not yet elucidated,
this observation suggests that the M glycoprotein can poten-
tially evolve and play a role during animal-to-human infection.
The E11A mutation that evolved during in vitro passages con-
ferred a selective in vitro replication advantage when intro-
duced in the SARS-CoV infectious molecular clone. The con-
sequent size and charge variation produced at the N-terminus
ectodomain of the M protein might affect the M function
either at the level of viral entry or assembly and budding. In
fact, the substitution for a negatively charged amino acid (glu-
tamic acid) with a nonpolar amino acid (alanine) might in-
crease the virus stickiness to the cell membrane, which is
usually negatively charged, by the presence of membrane gly-
cosaminoglycans and proteoglycans thus favoring the attach-
ment of the viral particles and engagement of the spike
proteins with ACE2. In addition, this mutation could improve
the M scaffolding function during virion budding into the lu-
men of the endoplasmic reticulum (22, 35). Of note is presence
of the same amino acid change in the mouse-adapted SARS-
CoV 15 (MA15) obtained after 15 serial passages in BALB/c
mice (43). The MA15 virus is characterized by a G-to-A sub-
stitution at position 26428 that leads to an E11K change in the
M protein. This mutation together with five other amino acid
changes, of which three are in ORF-1a, one is in ORF-1b, and
one is in S, cause disease and mortality in mice (43). The
coincidence of the same amino acid change in the M protein
following either in vitro or in vivo adaptation suggests that
position 11 plays a critical role for viral pathogenesis. In our in
vitro model, no changes occurred in the S, nucleocapsid, rep-
licase, or accessory proteins, in support of the observation that
a relative higher fixation rate and nonsilent/silent mutation
ratio occurred in the M protein compared to the other struc-
tural proteins during the epidemic in vivo (50; unpublished
observation).
In conclusion, our findings show that human kidney tubular
epithelial cells are permissive for productive SARS-CoV infec-
tion in vitro, explaining an unexplored but significant aspect of
SARS pathogenesis. Further investigation of our in vitro
model of SARS-CoV infectivity in different renal cells may
provide insights into understanding the mechanisms of kidney
injury, resulting in an unfavorable prognosis for many SARS
patients. Furthermore, our findings suggest that the kidney,
particularly tubular epithelial cells, might be a reservoir of
persistent SARS-CoV infection in vivo. The distinct outcome
of SARS-CoV infection in cells expressing ACE2 and possibly
L- or DC-SIGN could be used to search for host gene expres-
sion and/or signaling pathways playing a role in the establish-
ment of SARS-CoV replication and persistence as well as to
analyze the selection process underlying viral mutations favor-
ing persistence in human cells.
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